 The vast majority of deaths from ovarian cancer are from the high-grade serous cancer HGSC subtypes. The currently available tests for ovarian cancer diagnosis such as, blood tumour marker CA-125 and transvaginal ultrasound scan of the ovaries, have poor sensitivity and specificity therefore are not suitable for diagnosing early disease. Indeed, results from screening trials suggest that testing women in the general population for ovarian cancer may do more harm than good, due to the high proportion of false positive results. 